Guardant Health signed a multi‑year agreement with Merck to develop and commercialize companion diagnostics using Guardant’s liquid and tissue biopsy platforms to support patient enrollment across Merck’s global clinical studies. The collaboration links Merck’s trial pipelines with Guardant’s genomic profiling and seeks to streamline biomarker‑driven trial recruitment. The pact emphasizes the growing role of liquid biopsy in trial eligibility, real‑time monitoring and decentralized enrollment strategies. Guardant’s assays aim to identify patients for targeted therapies and could be deployed across multiple Merck programs worldwide. Partnerships of this type reduce friction between sponsors and diagnostic providers, accelerate biomarker qualification, and can shorten enrollment timelines for biomarker‑defined cohorts.